Skip to content
    HCA
    Earnings call· Jun 2026(Q2 FY26)

    HCA Healthcare, Inc. HCA

    Jul 24, 2026 Source

    Executive summary

    HCA Healthcare Q2 FY26 — Payer Mix Shift Impacts Earnings, Resiliency Program Advances

    HCA Healthcare navigated a challenging Q2 FY26 marked by a significant and worse-than-expected payer mix shift from health insurance exchanges to uninsured patients, primarily due to the expiration of enhanced premium tax credits. Despite this headwind, the company achieved solid diluted EPS growth and strong insured volume growth, while advancing its financial resiliency program to manage costs. Management is investing heavily in capacity expansion and believes positive demographic trends in its markets will support future demand.

    Highlights

    5
    • Diluted EPS grew 11% in the quarter and year-to-date.

    • Insured volumes, excluding exchanges, increased 3.2% in Q2 FY26, driven by ER visits, cardiac procedures, and rehab.

    • The financial resiliency program contributed to cost improvements, with same-facility cost per equivalent admission essentially flat YoY in Q2 FY26.

    • HCA Healthcare plans over $7 billion in capital expenditures for the next three years, including 1,000-1,200 new inpatient beds and 250-300 new outpatient facilities.

    • Positive demographic trends in HCA's markets (e.g., Florida, Texas, Utah) are expected to support long-term demand growth of 2-3%.

    Concerns

    5
    • An unfavorable payer mix shift, primarily due to the expiration of enhanced premium tax credits, resulted in an approximate $400 million negative impact on adjusted EBITDA in Q2 FY26.

    • Adjusted admissions for patients formerly covered by health insurance exchanges declined by 15%, with most migrating to uninsured status.

    • Inpatient surgeries decreased 2.3% and outpatient surgeries decreased 3.4% in Q2 FY26, with elective procedures particularly affected.

    • Full-year 2026 adjusted EBITDA guidance was revised down to $15.4 billion-$16.1 billion, reflecting the greater-than-expected impact of payer mix shifts.

    • A $100 million-$300 million headwind from Medicaid supplemental payment programs is anticipated in H2 FY26 due to prior-year retro payments exceeding new benefits.

    Guidance & targets

    11
    CategoryTargetConfidence
    Full-year 2026 Revenue
    $77 billion and $79.5 billion
    high materiality
    High
    Full-year 2026 Adjusted EBITDA
    $15.4 billion and $16.1 billion
    high materiality
    High
    Full-year 2026 Net income attributable to HCA Healthcare
    $6.3 billion and $6.7 billion
    medium materiality
    High
    Full-year 2026 Diluted Earnings Per Share
    $28.70 and $30.50
    high materiality
    High
    Full-year 2026 Health insurance exchanges impact on Adjusted EBITDA
    negative $1 billion and $1.2 billion
    high materiality
    High
    Full-year 2026 Medicaid supplemental payment program net benefit
    $300 million and $500 million
    high materiality
    High
    Full-year 2026 Capital expenditures
    $5 billion to $5.5 billion
    high materiality
    High
    Long-term Adjusted EBITDA growth rate target
    4% to 6%
    high materiality
    High
    Long-term demand growth
    2% to 3%
    medium materiality
    High
    Q4 2026 Adjusted EBITDA growth rate compared to prior year
    higher than for the third quarter
    low materiality
    Medium
    Attrition rates for exchanges
    less than 2026
    high materiality
    Medium

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    ASC business
    The ASC division experienced earnings growth, with slight volume increases driven by more units and growing case acuity.
    Overall volume in surgery center: up slightly year-over-yearAcuity of cases: growing
    earnings growth over the first 6 months of this year
    Gulf Coast division
    This division experienced an outsized impact from the HICS exchange volume shift, contributing significantly to the company's overall payer mix pressure.
    HICS adjusted admission decline: 25-28% for H1 FY26
    North Florida division
    This division experienced an outsized impact from the HICS exchange volume shift, contributing significantly to the company's overall payer mix pressure.
    HICS adjusted admission decline: 25-28% for H1 FY26
    South Atlantic division
    This division experienced an outsized impact from the HICS exchange volume shift, contributing significantly to the company's overall payer mix pressure.
    HICS adjusted admission decline: 25-28% for H1 FY26

    Operational metrics

    22
    Diluted EPS growth
    11%YoY
    Q2 FY26 and YTD FY26

    Solid diluted earnings per share growth.

    Same facility equivalent admissions growth (insured population excluding exchanges)
    3.2%YoY
    Q2 FY26

    Solid volume growth in insured population excluding exchanges.

    Same facility equivalent admissions growth (insured population excluding exchanges)
    2.2%YoY
    YTD FY26

    Solid volume growth in insured population excluding exchanges.

    Same facility cost per equivalent admission
    essentially flatYoY
    Q2 FY26

    Pleased with cost results in Q2.

    Same facility cost per equivalent admission
    improved 1.4%sequentially
    Q2 FY26

    Pleased with cost results in Q2.

    Capital expenditures
    $1.2 billion
    Q2 FY26

    Total capital expenditures for the quarter.

    Share repurchases
    $2.1 billion
    Q2 FY26

    Amount of outstanding shares purchased.

    Dividends paid
    $171 million
    Q2 FY26

    Dividends paid for the quarter.

    Debt to adjusted EBITDA leverage
    lower half of our stated target range
    Q2 FY26

    Balance sheet remains strong and well positioned.

    Inpatient capacity added
    5,000 beds
    since 2018

    Added to inpatient chassis over the past 5-6 years.

    Occupancy level
    grown from 71% to 75%
    since 2018

    Utilization of capacity has grown.

    Sites of care
    5% moreYoY
    Q2 FY26 vs Q2 FY25

    Continued to add to outpatient network.

    Planned outpatient facilities
    another 250 to 300
    later this year and early next year

    Either in capital plan or acquisition plans.

    Same facility professional fees growth
    8.5%YoY
    Q2 FY26

    Professional fees are still elevated but showing stability, moderated and flat sequentially to Q1.

    Same facility professional fees growth
    almost 10%YoY
    YTD FY26

    Professional fees are still elevated but showing stability.

    Uninsured equivalent admissions growth
    15%YoY
    Q2 FY26

    Total uninsured equivalent admissions increased.

    Uninsured equivalent admissions as % of total
    a little over 10%
    Q2 FY26

    Uninsured now represents a significant portion of total equivalent admissions.

    Exchange equivalent admissions as % of total
    about 6.8%
    Q2 FY26

    Health insurance exchanges represent a smaller portion of total equivalent admissions after declines.

    Health care exchange equivalent admissions decline
    about 22,000YoY
    YTD FY26

    Number of patients lost from health care exchanges.

    Uninsured equivalent admissions increase
    about 26,500YoY
    YTD FY26

    Number of uninsured patients gained, showing a one-for-one migration from exchanges.

    Medicaid revenues in expansion states
    40%
    current

    Portion of Medicaid revenues from expansion states, relevant for work requirements impact.

    Medicaid revenues in non-expansion states
    60%
    current

    Portion of Medicaid revenues from non-expansion states, relevant for work requirements impact.

    Industry KPIs

    4
    MetricValueDetails
    Utilization trends2.5% increasepercent
    Same facility volumes2.5% increasepercent
    Payer mix supplemental paymentsbetween $300 million and $500 millionUSD
    Adjusted EPS EBITDA leverage guidancebetween $15.4 billion and $16.1 billionUSD

    Deals & partnerships

    1
    ValescoAcquisition of Valesco to gain control of hospital-based services.

    The acquisition of Valesco allowed HCA to integrate hospital-based services into contracts with appropriate reimbursement, stabilizing emergency room and hospital medicine physician components.

    Risks & headwinds

    4
    Expiration of enhanced premium tax credits and resulting payer mix shiftQ2 FY26, FY26

    unfavorable impact on adjusted EBITDA of approximately $400 million in Q2 FY26; between a negative $1 billion and $1.2 billion for FY26. Adjusted admissions for former exchange patients declined by 15%.

    Mitigation: Advancing financial resiliency program, capital investments to expand capacity, adapting to market dynamics, and leveraging strong balance sheet.

    Decline in elective surgeriesQ2 FY26, YTD FY26

    Inpatient surgeries down 2.3%, outpatient surgeries down 3.4% in Q2 FY26. Elective inpatient down 6% (vs 2% last year) YTD FY26.

    Mitigation: Investing in ORs, optimizing operations, aligning with physicians, and expanding the ASC business to offer multiple options for patients and physicians.

    Medicaid supplemental payment program headwindH2 FY26

    $100 million to $300 million headwind in H2 FY26.

    Mitigation: Implied management of operational efficiency and cost controls to mitigate the impact.

    Medicaid work requirements2027

    Expected to have an impact, particularly in expansion states (40% of Medicaid revenues).

    Mitigation: Monitoring proposed rule, working with states on implementation, and beefing up coverage benefit support teams in facilities to help patients with application and work requirements processes.

    What to watch in Q3 FY26

    4

    Exchange coverage attrition rate

    2027
    Current15% decline in adjusted admissions for former exchange patients in Q2 FY26, with almost one-for-one migration to uninsured.
    TargetLess than 2026 attrition rate

    Why it matters

    Determines the ongoing impact of payer mix shift on profitability and uncompensated care, crucial for future revenue and margin stability.

    As we think about attrition rates for the exchanges in 2027, we believe it's reasonable to estimate at this point, even with premium increases that we're starting to see that the loss of coverage will be less than 2026.

    Q&A highlights

    5

    Clarification on the increased estimate for exchange headwinds ($1B-$1.2B), confidence in the magnitude, and pacing through H2.

    Mike Marks explained that the original assumption of 80-85% of patients losing exchange coverage becoming uninsured was revised to almost one-for-one based on Q2 data. Volume declines were in line, but the migration to uninsured was higher. H2 guidance incorporates this, noting an easier comparison in Q4 2025 due to early exchange reforms.

    What's different as we have gone through second quarter is that we originally have seen that about 80% to 85% of the patients who lose exchange coverage would become uninsured. And our data is telling us now that it's closer to one-for-one.

    asked by Benjamin Hendrix · answered by Mike Marks

    3 min read6 chapters

    Detailed Narrative

    01

    Impact of Expired Enhanced Premium Tax Credits

    The expiration of enhanced premium tax credits led to a significant and worse-than-expected payer mix shift, with adjusted admissions for former exchange patients declining by 15%. This resulted in an almost one-for-one migration to uninsured status, impacting adjusted EBITDA by approximately $400 million in Q2 FY26. Three divisions (Gulf Coast, North Florida, South Atlantic) accounted for about 50% of this impact, experiencing 25-28% declines in HICS adjusted admissions. The full-year 2026 estimated impact on adjusted EBITDA from health insurance exchanges is now negative $1 billion to $1.2 billion.

    02

    Volume Trends and Surgical Performance

    Despite the challenging payer mix shift, insured volumes (excluding exchanges) increased by 3.2% in Q2 FY26 and 2.2% year-to-date, driven by solid trends in ER visits (+3.6%), cardiac procedures, and rehab volumes. However, inpatient surgeries were down 2.3% and outpatient surgeries down 3.4% in Q2. Elective surgeries, particularly, saw declines (inpatient elective down 6% YTD), partly attributed to HICS demand and general economic affordability pressures. Emergency inpatient surgeries, representing two-thirds of inpatient cases, were up 2% year-over-year.

    03

    Medicaid Supplemental Payment Programs

    HCA recognized approximately $400 million of incremental net benefit from Medicaid supplemental payment programs in Q2 FY26. This included a $540 million incremental net benefit related to the recently approved Florida program, covering the period from October 1, 2024, to June 30, 2026. This benefit was partially offset by retro payments received in Q2 FY25. The full-year 2026 guidance for Medicaid supplemental payment net benefit is $300 million to $500 million, implying a $100 million to $300 million headwind in H2 FY26.

    04

    Financial Resiliency Program and Cost Management

    The company is advancing a long-term, multifaceted financial resiliency program focused on digital transformation, global capabilities, and enhanced workforce development. This program contributed to cost improvements, with same-facility cost per equivalent admission (considering Medicaid supplemental payment programs) essentially flat year-over-year in Q2 FY26 and improving 1.4% sequentially. Management is confident this program will continue to improve cost trends in H2 FY26 and into 2027, producing multi-year benefits.

    05

    Capital Allocation and Capacity Expansion

    HCA has approved over $7 billion in capital expenditures for the next three years, aimed at increasing capacity and improving competitive positioning. This includes adding 1,000 to 1,200 inpatient beds and 250-300 new outpatient facilities, which will add approximately 10% to the overall network capacity. The company's total sites of care increased by 5% year-over-year in Q2 FY26. These investments are supported by positive demographic trends in HCA's key markets, which are expected to drive long-term demand growth of 2-3%.

    06

    Medicaid Work Requirements and Future Outlook

    Management is monitoring proposed Medicaid work requirements, anticipating a greater impact in expansion states, where 40% of HCA's Medicaid revenues originate. While acknowledging potential impacts, HCA believes it can manage through these changes by leveraging its coverage benefit support teams and strategic asset distribution. For 2027, the company estimates that coverage loss from exchanges will be less than in 2026, assuming no new enhanced premium support, as the primary driver of 2026 attrition (expiration of enhanced premium tax credits) will have passed.

    AI-generated summary of the company’s earnings call. Not investment advice.